[Form 4] GRI Bio, Inc. Insider Trading Activity
GRI Bio, Inc. director Camilla V. Simpson was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share. The option appears in Table II as a derivative security with an expiration date of 08/13/2035. The filing states the option vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date. The reporting person is shown as a director and the Form 4 was signed by an attorney-in-fact on 08/14/2025.
GRI Bio, Inc. la direttrice Camilla V. Simpson ha ricevuto un’opzione su azioni il 13/08/2025 per acquistare 4.527 azioni ordinarie a un prezzo di esercizio di $1,30 per azione. L’opzione è riportata nella Tabella II come strumento derivato con scadenza il 13/08/2035. La documentazione indica che l’opzione matura in quattro rate trimestrali uguali ed è completamente maturata al primo anniversario della data di concessione. La persona che effettua la comunicazione risulta essere una direttrice e il Modulo 4 è stato firmato da un procuratore il 14/08/2025.
GRI Bio, Inc. la directora Camilla V. Simpson recibió una opción sobre acciones el 13/08/2025 para comprar 4.527 acciones ordinarias a un precio de ejercicio de $1.30 por acción. La opción figura en la Tabla II como un valor derivado con fecha de vencimiento el 13/08/2035. El documento indica que la opción vence en cuatro cuotas trimestrales iguales y queda totalmente consolidada al primer aniversario de la fecha de concesión. La persona informante aparece como directora y el Formulario 4 fue firmado por un apoderado el 14/08/2025.
GRI Bio, Inc.의 이사 Camilla V. Simpson은 2025-08-13에 보통주 4,527주를 주당 $1.30의 행사가격으로 매수할 수 있는 스톡옵션을 부여받았습니다. 해당 옵션은 파생증권으로 표 II에 기재되어 만기일이 2035-08-13로 되어 있습니다. 제출서류에는 옵션이 동일한 4번의 분기별 할부로 베스트(취득)되며 부여일로부터 1주년에는 완전히 베스트된다고 명시되어 있습니다. 보고자는 이사로 기재되어 있으며 Form 4는 2025-08-14에 대리인이 서명했습니다.
GRI Bio, Inc. la administratrice Camilla V. Simpson s’est vu accorder une option d’achat d’actions le 13/08/2025 portant sur 4 527 actions ordinaires au prix d’exercice de 1,30 $ par action. L’option apparaît dans le Tableau II comme un titre dérivé avec une date d’expiration au 13/08/2035. Le dossier indique que l’option devient acquise en quatre versements trimestriels égaux et est entièrement acquise à la date du premier anniversaire de la concession. La personne déclarée figure en tant qu’administratrice et le formulaire 4 a été signé par un mandataire le 14/08/2025.
GRI Bio, Inc.-Direktorin Camilla V. Simpson erhielt am 13.08.2025 eine Aktienoption zum Kauf von 4.527 Stammaktien zu einem Ausübungspreis von $1,30 je Aktie. Die Option ist in Tabelle II als derivates Wertpapier mit Ablaufdatum 13.08.2035 aufgeführt. In der Einreichung heißt es, die Option fällt in vier gleiche vierteljährliche Tranchen und ist zum ersten Jahrestag des Gewährungsdatums vollständig unverfallbar. Die meldende Person wird als Direktorin ausgewiesen und das Formular 4 wurde am 14.08.2025 von einem Bevollmächtigten unterzeichnet.
- 4,527 stock options granted to director Camilla V. Simpson are disclosed, including exercise price $1.30 and expiration 08/13/2035
- Vesting schedule is specified: four equal quarterly installments, fully vested on the first anniversary of the grant
- None.
Insights
TL;DR: Director Camilla Simpson received a 4,527-option grant at $1.30, expiring 08/13/2035; vests over one year in quarterly installments.
The Form 4 documents a compensatory equity award to an insider, specifying the grant size, exercise price, and a ten-year expiration. For investors, this is a routine disclosure of insider compensation and ownership change. The grant increases the director's potential equity stake if exercised, and the vesting schedule ties realization to continued service during the next year. The filing contains clear transaction date and expiration details and is properly executed by an attorney-in-fact.
TL;DR: Standard director option award recorded; vesting over four quarterly installments with a ten-year term is disclosed.
The disclosure is concise and follows Section 16 reporting requirements. The grant's vesting schedule—four equal quarterly installments culminating at one year—is explicitly stated, which clarifies when economic benefit accrues to the reporting person. The Form identifies the reporting person as a director and includes signature via attorney-in-fact. No amendments, other arrangements, or additional beneficial ownership details are provided in this filing.
GRI Bio, Inc. la direttrice Camilla V. Simpson ha ricevuto un’opzione su azioni il 13/08/2025 per acquistare 4.527 azioni ordinarie a un prezzo di esercizio di $1,30 per azione. L’opzione è riportata nella Tabella II come strumento derivato con scadenza il 13/08/2035. La documentazione indica che l’opzione matura in quattro rate trimestrali uguali ed è completamente maturata al primo anniversario della data di concessione. La persona che effettua la comunicazione risulta essere una direttrice e il Modulo 4 è stato firmato da un procuratore il 14/08/2025.
GRI Bio, Inc. la directora Camilla V. Simpson recibió una opción sobre acciones el 13/08/2025 para comprar 4.527 acciones ordinarias a un precio de ejercicio de $1.30 por acción. La opción figura en la Tabla II como un valor derivado con fecha de vencimiento el 13/08/2035. El documento indica que la opción vence en cuatro cuotas trimestrales iguales y queda totalmente consolidada al primer aniversario de la fecha de concesión. La persona informante aparece como directora y el Formulario 4 fue firmado por un apoderado el 14/08/2025.
GRI Bio, Inc.의 이사 Camilla V. Simpson은 2025-08-13에 보통주 4,527주를 주당 $1.30의 행사가격으로 매수할 수 있는 스톡옵션을 부여받았습니다. 해당 옵션은 파생증권으로 표 II에 기재되어 만기일이 2035-08-13로 되어 있습니다. 제출서류에는 옵션이 동일한 4번의 분기별 할부로 베스트(취득)되며 부여일로부터 1주년에는 완전히 베스트된다고 명시되어 있습니다. 보고자는 이사로 기재되어 있으며 Form 4는 2025-08-14에 대리인이 서명했습니다.
GRI Bio, Inc. la administratrice Camilla V. Simpson s’est vu accorder une option d’achat d’actions le 13/08/2025 portant sur 4 527 actions ordinaires au prix d’exercice de 1,30 $ par action. L’option apparaît dans le Tableau II comme un titre dérivé avec une date d’expiration au 13/08/2035. Le dossier indique que l’option devient acquise en quatre versements trimestriels égaux et est entièrement acquise à la date du premier anniversaire de la concession. La personne déclarée figure en tant qu’administratrice et le formulaire 4 a été signé par un mandataire le 14/08/2025.
GRI Bio, Inc.-Direktorin Camilla V. Simpson erhielt am 13.08.2025 eine Aktienoption zum Kauf von 4.527 Stammaktien zu einem Ausübungspreis von $1,30 je Aktie. Die Option ist in Tabelle II als derivates Wertpapier mit Ablaufdatum 13.08.2035 aufgeführt. In der Einreichung heißt es, die Option fällt in vier gleiche vierteljährliche Tranchen und ist zum ersten Jahrestag des Gewährungsdatums vollständig unverfallbar. Die meldende Person wird als Direktorin ausgewiesen und das Formular 4 wurde am 14.08.2025 von einem Bevollmächtigten unterzeichnet.
FAQ
What did Camilla V. Simpson report on Form 4 for GRI (GRI)?
When do the options granted to Camilla V. Simpson vest?
How many shares underlying the derivative were reported as beneficially owned after the transaction?
What is the relationship of the reporting person to GRI Bio, Inc.?
Who signed the Form 4 filing and when was it signed?
